Assessment of Binding Site and Development of Small Molecule Inhibitors
Targeting Epidermal Growth Factor Receptor Mutations in Non-Small
Cell Lung Cancer (NSCLC)
-
Published:2023-09
Issue:9
Volume:20
Page:1204-1218
-
ISSN:1570-1808
-
Container-title:Letters in Drug Design & Discovery
-
language:en
-
Short-container-title:LDDD
Author:
Wakte Pravin S.1,
Karnik Kshipra S.1,
Sarkate Aniket P.1,
Rajhans Aishwarya P.1
Affiliation:
1. Department of Chemical Technology, Dr. Babasaheb Ambedkar Marathwada University, Aurangabad (MS) 431004,
India
Abstract
Background:
Mutations occurring in the epidermal growth factor receptor of the tyrosine ki.nase family concerned with non-small cell lung cancer have been specifically targeted.
Objectives:
The library design and R-group enhancement technique have been carried out on the pre.existing marketed drugs to increase the binding affinity of the designed novel compounds. The screening
of compounds was done using a flexible docking protocol.
Methods:
Molecular docking studies provided information about binding pockets and interactions of mol.ecules with the mutant (PDB: 4I1Z) as well as wild-type (PDB: 4I23) EGFR enzymes. The flexible dock.ing was well supported by ADMET and molecular dynamic simulation studies.
Results:
On the basis of docking score and protein-ligand interactions, the highest-scoring molecule was
selected for molecular dynamics simulation, providing a complete insight into the ligand interaction and
saturation
Conclusion:
The screened molecules can act as potential EGFR inhibitors in the management of drug
resistance.
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine